1 / 7

Glioblastoma Multiforme Therapeutics in Major Developed Mark

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany.

hsdfg
Download Presentation

Glioblastoma Multiforme Therapeutics in Major Developed Mark

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals & Healthcare Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

  2. Synopsis GBI Research, a leading business intelligence provider, has released its latest research report, "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany". Browse complete Report http://www.aarkstore.com/pharmaceuticals-healthcare/94560/glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2020-growth-to-hinge-on-the-success-of-personalized-vaccine-following-early-approval-in-germany

  3. Summary Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Mercks Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roches Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

  4. Table of contents 1 Table of Contents 41.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 Disease Introduction 82.2 Classification of Brain Tumors 92.3 Tumor Grading 112.4 Subtypes of Glioblastoma Multiforme 122.5 Etiology 122.6 Pathophysiology 13

  5. Related Reports • http://www.aarkstore.com/pharmaceuticals-healthcare/110859/mens-health-changing-male-attitudes-to-health-to-improve-prognosis-and-outcomes • http://www.aarkstore.com/pharmaceuticals-healthcare/110732/almac-discovery-ltd-product-pipeline-review-2015 • http://www.aarkstore.com/pharmaceuticals-healthcare/110731/summit-corporation-plc-product-pipeline-review-2015 • http://www.aarkstore.com/pharmaceuticals-healthcare/110730/valentia-biopharma-sl-product-pipeline-review-2015 • http://www.aarkstore.com/pharmaceuticals-healthcare/110729/immunomic-therapeutics-inc-product-pipeline-review-2015

  6. Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany Published: June 2014 – 112 Pages Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany Price

  7. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related